CYTOSORBENTS CORP's ticker is CTSO and the CUSIP is 23283X206. A total of 103 filers reported holding CYTOSORBENTS CORP in Q2 2021. The put-call ratio across all filers is 2.91 and the average weighting 0.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $224 | -47.5% | 119,100 | +0.2% | 0.00% | -100.0% |
| Q2 2023 | $427 | +6.8% | 118,900 | +0.3% | 0.00% | 0.0% |
| Q1 2023 | $400 | +117.4% | 118,600 | +0.2% | 0.00% | – |
| Q4 2022 | $184 | -99.9% | 118,400 | -40.1% | 0.00% | – |
| Q3 2022 | $269,000 | -12.4% | 197,796 | +41.2% | 0.00% | – |
| Q2 2022 | $307,000 | +13.3% | 140,120 | +65.0% | 0.00% | – |
| Q1 2022 | $271,000 | -74.4% | 84,900 | -39.4% | 0.00% | -100.0% |
| Q2 2021 | $1,058,000 | -32.3% | 140,100 | -22.2% | 0.00% | -50.0% |
| Q1 2021 | $1,562,000 | +167.9% | 180,000 | +146.2% | 0.00% | +100.0% |
| Q4 2020 | $583,000 | -23.9% | 73,100 | -23.9% | 0.00% | 0.0% |
| Q3 2020 | $766,000 | +160.5% | 96,000 | +147.4% | 0.00% | – |
| Q1 2019 | $294,000 | -70.1% | 38,800 | -68.1% | 0.00% | -100.0% |
| Q4 2018 | $983,000 | -62.6% | 121,700 | -47.2% | 0.00% | 0.0% |
| Q2 2018 | $2,625,000 | – | 230,300 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| CM Management, LLC | 675,000 | $918,000 | 1.02% |
| Sargent Investment Group, LLC | 1,108,233 | $2,028,000 | 0.63% |
| Skylands Capital, LLC | 2,347,034 | $3,192,000 | 0.52% |
| JACOB ASSET MANAGEMENT OF NEW YORK LLC | 253,000 | $344,000 | 0.37% |
| Avenir Corp | 2,314,854 | $3,148,000 | 0.33% |
| Granahan Investment Management | 1,511,029 | $2,055,000 | 0.07% |
| ACT CAPITAL MANAGEMENT, LLC | 35,000 | $48,000 | 0.07% |
| Winning Points Advisors, LLC | 22,900 | $33,000 | 0.04% |
| Cowen Prime Advisors LLC | 42,200 | $57,000 | 0.03% |
| Seelaus Asset Management LLC | 23,900 | $33,000 | 0.03% |